일리노이의 버킷 림프종 임상 시험
버킷 림프종 관련 연구 13개가 일리노이 내 여러 지역에서 참여자를 모집하고 있습니다.
일리노이의 도시
공식 연구 텍스트(영어)
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- 외 9개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT03739814A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- 외 4개
피험자 모집 중2상
366 Days – 46 Years · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- 외 3개
피험자 모집 중2상
365 Days · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06317662Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- 외 7개
피험자 모집 중3상
18세 ~ 39세 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT03150693A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- 외 2개
피험자 모집 중2상
1세 ~ 30세 · 모든 성별 · 2026. 9. 1. 업데이트됨 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- 외 5개
피험자 모집 중3상
365 Days – 25 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT03959085AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Chicago
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT06137118Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
피험자 모집 중2상
7세 ~ 25세 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT05082519Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Chicago
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT07109219Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
피험자 모집 중2상
18세 ~ 54세 · 모든 성별 · 2026. 3. 17. 업데이트됨 · NCT06918431ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- University of Chicago Comprehensive Cancer Center, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 11. 4. 업데이트됨 · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- University of Chicago, Chicago
피험자 모집 중1/2상
15세 ~ 50세 · 모든 성별 · 2025. 9. 9. 업데이트됨 · NCT04150497Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
피험자 모집 중
18세 ~ 50세 · 모든 성별 · 2025. 6. 19. 업데이트됨 · NCT06785324ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.